Table 3.

Seasonal prevalence of short- and long-term relapses in three treatment groups

TreatmentNo. (%) of cases
TotalNonrelapseRelapseRelapse period of:
<6 mo (short term)>6 mo, <12 mo (long term)
First half (January to June)
 Bulaquine (a)40241613 (32.5)3 (7.5)
 Primaquine (b)46351111 (23.91)0 (0.00)
 Combined (a + b)86592724 (27.91)3 (3.49)
 Placebo49311816 (32.65)2 (4.08)
Second half (July to December)
 Bulaquine (a)1791304921 (11.73)28 (15.64)
 Primaquine (b)1741264825 (14.37)23 (13.22)
 Combined (a + b)3532569745 (12.75)52 (14.73)
 Placebo1751037226 (14.86)46 (26.29)